ERBB2 and breast cancer: TKIs in combination with trastuzumab can comprehensively block both intracellular and extracellular domains and significantly improve anti-HER2 treatment efficacy, which has been demonstrated in the treatment of early-stage BC (Wu et al. 2022; Llombart-Cussac et al. 2017).